DPX-Survivac, The First of IMV’s New Class of Immunotherapies
Generating Cancer-Targeted Killer T Cells
DPX-Survivac, which combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in vivo.
The protein survivin is found in more than 15 types of solid tumor and hematologic cancers. It has been recognized as a promising tumor-associated target because it is overexpressed in a high percentage of tumor types. Survivin plays a critical role in tumor biology as it is associated with tumor cell differentiation, proliferation, invasion and metastasis1. We believe DPX-Survivac’s ability to deliver a sustained flow of T cells that target survivin expressed on cancer cells can lead to more clinically effective anti-tumor therapies.
DPX-Survivac has demonstrated a robust and sustained, antigen-specific immune response with infiltration of targeted T cells into tumors post treatment which is correlated with prolonged duration of clinical benefits up to more than two years. DPX-Survivac showed a well-tolerated safety profile with no immune-related, serious systemic adverse events reported. Majority of adverse events being grade 1 and 2 injection site reactions2,3. Compared to traditional immuno-oncology therapies, which require intravenous infusions and safety monitoring, DPX-Survivac provides lesser burden on patients’ quality of life.
DPX-Survivac Mechanism of Action in Advanced, Recurrent Ovarian Cancer